Biomedical subjects

Y J Gordon

Publications and source records attributed to Y J Gordon.

At least 19 recordsLinked to original sources

PubMed2001

Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.

PURPOSE: The goal of this study was to determine the effects of concurrent therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) on the antiviral activity of cidofovir on adenovirus replication and the formation of subepithelial infiltrates in the Ad5/New Zealand White rabbit ocular model. METHODS: According to two protocols, 20 rabbits were inoculated in both eyes with Ad5 topically to study adenovirus replication, and 20 rabbits were inoculated in both eyes topically and intrastromally to study the formation of subepithelial infiltrates. Animals were randomized to four masked treatment groups: group I, 0.5% cidofovir + artificial tears; group II, 0.5% cidofovir + 0.5% ketorolac tromethamine; group III, 0.5% cidofovir + 0.1% diclofenac sodium; and group IV, control + artificial tears. Cidofovir and control were administered to both eyes twice daily for 7 days, and artificial tears, ketorolac, and diclofenac four times daily for 14 days. Eyes were cultured on days 0, 1, 3, 4, 5, 7, 9, 11, and 14. RESULTS: Compared with the control group, all cidofovir-treated groups demonstrated significant antiviral effects on adenovirus replication. There were no differences in adenovirus replication among the cidofovir-treated groups (I, II, and III), nor were there any differences among all groups (I-IV) in the formation of subepithelial infiltrates. CONCLUSIONS: Concurrent treatment of ketorolac or diclofenac with cidofovir did not diminish its antiviral inhibitory activity on adenovirus replication, nor did it prevent the formation of subepithelial infiltrates in the rabbit model.

Adenovirus Infections, Human↗

PubMed2000

The evolution of antiviral therapy for external ocular viral infections over twenty-five years.

PURPOSE: To review the past 25 years of the evolution of antiviral therapy for the treatment of common external ocular viral infections (herpes simplex virus type 1, varicella-zoster virus, and adenovirus). METHODS: A broad-based literature review in the fields of virology, antiviral research, and ophthalmology will be carried out. The pathogenesis of the major external ocular viral infections and history of antiviral development will be cited. Important conceptual breakthroughs as well as historical landmarks will be emphasized. RESULTS: The successful development of effective antivirals to treat the most common external ocular viral infections have dramatically reduced morbidity and sight loss. The immune pathogenesis of herpetic stromal keratitis is better understood. CONCLUSIONS: Remarkable progress in the development of antiviral therapy has occurred over the past quarter century. Future needs include improved antivirals and immunomodulators and vaccines to prevent and treat herpetic ocular infections and adenovirus keratoconjunctivitis.

Antiviral Agents↗

PubMed2000

Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.

PURPOSE: The goal of the present study was to determine the efficacy of topical 0.5% cidofovir twice daily for 7 days on the replication of multiple adenovirus (Ad) serotypes of subgroup C (Ad1, Ad5, Ad6) in the New Zealand rabbit ocular model. METHODS: In duplicate experiments for each serotype, a total of 20 rabbits (Ad5) or 16 rabbits each (Ad1 and Ad6) were inoculated topically in both eyes, with 1.5 X 10(6) pfu/eye of the appropriate virus. Twenty-four hours later, the rabbits in each serotype group were randomly divided into two topical treatment groups: I, 0.5% cidofovir; II, control vehicle. Treatment was twice daily for 7 days. All eyes were cultured for virus on days 0, 1, 3, 4, 5, 7, 9, 11, and 14. RESULTS: Compared to the control, treatment with 0.5% cidofovir reduced the following: mean Ad titer (days 1 to 7) for Ad1 (6.3 +/- 20 x 10(1) versus 2.5 +/- 3.9 X 102 pfu/ml; P < 0.0003), Ad5 (3.4 +/-5.8 x 102 versus 1.6 +/- 2.0 x 10(3) pfu/ml; P < 0.000001), and Ad6 (1.2 +/- 5.1 x 10(2) versus 5.5 +/-14 x 10(2) pfu/ml; P = 0.015); reduced Ad-positive eyes/total for Adl [45/128 (35%) versus 84/128 (66%); P = 0.000002], Ad5 [84/160 (53%) versus 131/152 (86%); P < 0.000001], and Ad6 [36/128 (28%) versus 82/128 (64%); P < 0.000001]: and reduced the duration of Ad shedding forAdl (4.9 +/-1.9 versus 9.3 +/- 3.3 days; P < 0.00007), Ad5 (6.4 +/- 2.8 versus 11.5 +/- 2.3 days; P < 0.0001), and Ad6 (4.4 +/- 2.1 versus 8.4 +/- 2.5 days; P < 0.00004). CONCLUSIONS: Topical 0.5% cidofovir twice daily for 7 days demonstrated significant antiviral activity against multiple adenoviral serotypes (Ad1, Ad5, and Ad6) in the New Zealand rabbit ocular model. These in vivo data expand in vitro studies indicating the efficacy of cidofovir against different adenovirus serotypes and support its use in clinical trials.

Adenovirus Infections, Human↗

PubMed1999

The survival of herpes simplex virus in multidose office ophthalmic solutions.

PURPOSE: To determine the survival of herpes simplex virus type 1 (HSV-1) in several multidose ophthalmic solutions. METHODS: In three separate trials, 10 aliquots of 5 ml each of three common multidose topical ophthalmic solutions, sodium fluorescein, proparacaine, and nonpreserved artificial tears, were inoculated with 10(5), 10(4), and 10(3) pfu per ml of HSV-1. All samples were titered on A549 cells at various time points for surviving HSV-1. RESULTS: Herpes simplex virus type 1 was not recovered from the fluorescein and proparacaine solutions at 1 hour or any time thereafter, regardless of inoculation titer. Herpes simplex virus type 1 was recovered from the artificial tears up to 7 days. CONCLUSION: Unlike adenovirus, HSV-1 does not survive in preserved fluorescein and proparacaine multidose solutions; therefore, office transmission is highly unlikely.

Benzalkonium Compounds↗

PubMed1999

Evaluation of the shell vial technique for detection of ocular adenovirus. Community Ophthalmologists of Pittsburgh, Pennsylvania.

PURPOSE: The shell vial technique is a cell culture method that uses centrifugation and immunofluorescence to decrease the time required for a positive test. The authors evaluated the shell vial technique as a diagnostic test to detect adenovirus in conjunctival specimens of patients with adenoviral conjunctivitis. DESIGN: Retrospective and prospective case series. PARTICIPANTS: Forty-six patients with adenoviral culture-positive ocular infection. METHODS: The minimum time of incubation (days) that was required for testing clinical isolates with the shell vial was determined with adenovirus serotypes 5 and 8. In a masked retrospective study, 25 true-positive (frozen clinical samples) and 25 true-negative specimens were tested for the presence of adenovirus using the shell vial technique. The 25 true-negative samples included herpes simplex virus, Chlamydia trachomatis, Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus. In a prospective study, 21 patients who later tested positive in cell culture for adenovirus were concurrently tested with shell vial. MAIN OUTCOME MEASURES: The time of incubation was determined in days, and the sensitivity, specificity, positive and negative predictive values, and the efficacy of the shell vial test were determined. RESULTS: The minimal time of incubation for testing ocular samples by shell vial was 3 days. In the retrospective study, the sensitivity, specificity, positive predictive value, negative predictive value, and efficacy were 92%, 100%, 100%, 93%, and 96%, respectively. Comparably (P = 0.99), in the prospective study the sensitivity, specificity, positive predictive value, negative predictive value, and efficacy were 95%, 100%, 100%, 96%, and 97%, respectively. The shell vial (93%, 43 of 46) was equivalent (P = 0.42) to cell culture (100%, 46 of 46) for detecting adenovirus, but a positive result was obtained in significantly less time (3 days versus 9.41 +/- 6.23 days) (P = 0.00001). CONCLUSIONS: The shell vial technique was found to be a definitive method for identifying adenovirus from ocular specimens. A clear benefit for the ophthalmologist is that the test can provide a faster positive result (3 days) compared with conventional cell culture, which can take 1 to 3 weeks for adenovirus isolation.

Adenovirus Infections, Human↗

PubMed1999

Valacyclovir inhibits recovery of ocular HSV-1 after experimental reactivation by excimer laser keratectomy.

PURPOSE: The goal of this was to determine whether the systemic administration of valacyclovir (Valtrex) would reduce ocular shedding of herpes simplex virus 1 (HSV-1) after excimer laser ablation in the New Zealand rabbit latency model. METHODS: The in vitro 50% inhibitory concentration (IC50) of HSV-1 W strain was determined by using a plaque-reduction assay to verify its sensitivity to acyclovir. Forty-seven NZW rabbits latently infected with HSV-1 W strain were divided into four groups: I, 50 mg/kg/day valacyclovir; II, 100 mg/kg/day valacyclovir; III, 150 mg/kg/day valacyclovir; and IV, saline control. One half of the total dose of valacyclovir was delivered via intraperitoneal injections twice daily for 7 days beginning with one dose before excimer laser keratectomy. HSV-1 ocular shedding was determined from eye cultures for 7 days after treatment. RESULTS: The IC50 for HSV-1 W was determined to be 2.9 microg/ml. The administration of both 100 mg/kg/day (group II) and 150 mg/kg/day (group III) of valacyclovir significantly reduced the number of eyes from which latent HSV-1 was recovered compared with the control group. There was no difference between the control group and group I (50 mg/kg/day valacyclovir). However, all three valacyclovir dosages significantly reduced the total number of HSV-1 shedding days compared with the control group, and 100% HSV-1 TG latency was demonstrated for all four groups. CONCLUSION: Systemic administration of valacyclovir significantly reduced HSV-1 ocular shedding in a dose-dependent manner after excimer laser keratectomy in the NZW rabbit latency model.

Acyclovir↗

PubMed1999

Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.

OBJECTIVE: To identify resistance patterns to the fluoroquinolones for patients with bacterial keratitis. DESIGN: Retrospective observational case series. PARTICIPANTS: All cases of bacterial keratitis presenting to the Charles T. Campbell Ophthalmic Microbiology Laboratory at the Eye and Ear Institute of Pittsburgh from January 1993 to December 1997 were reviewed. A total of 1053 ocular isolates from 825 cases of bacterial keratitis were identified. MAIN OUTCOME MEASURES: In vitro laboratory susceptibility testing of ocular isolates to ciprofloxacin and ofloxacin was determined by the Kirby-Bauer disk diffusion method and interpreted using the National Committee for Clinical Laboratory Standards serum standards. RESULTS: The number of cases of bacterial keratitis per year decreased from 284 in 1993 to 75 in 1997. The ratio of gram-positive to gram-negative organisms changed from 81.8%:18.2% in 1993 to 51.4%:48.6% in 1997 (chi-square, 66.00; degrees of freedom, 4; P < 0.000001). Resistance of Staphylococcus aureus to ciprofloxacin significantly increased annually from 5.8% in 1993 to 35.0% in 1997 (chi-square, 19.80; degrees of freedom, 4; P < 0.0001) and for ofloxacin from 4.7% to 35.0% over the same period (chi-square, 21.32; degrees of freedom, 4; P < 0.001). Streptococcus species and coagulase-negative Staphylococcus species showed significant resistance to both fluoroquinolones but no change in resistance over the study period. The gram-negative organisms showed good susceptibility to the fluoroquinolones. CONCLUSIONS: This in vitro study shows a significant increased resistance of S. aureus to the fluoroquinolones from 1993 to 1997. In addition, gaps in fluoroquinolone coverage for Streptococcus and coagulase-negative Staphylococcus species raise concern for the use of monotherapy in treating bacterial keratitis. Contrary to what might be expected, the distribution of gram-positive to gram-negative organisms has shifted, with a decrease in the number of gram-positive organisms identified, while the number of gram-negative isolates has remained stable.

Anti-Infective Agents↗

PubMed1999

Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.

PURPOSE: To determine the relative antiviral inhibitory activity of topical 1% and 0.5% cidofovir, topical trifluridine (Viroptic; Burroughs-Wellcome, Research Triangle Park, NC), and topical acyclovir (Zovirax; The Wellcome Foundation, London, UK) during a 7-day period for the treatment of herpes simplex virus type 1 (HSV-1) keratitis and HSV-1 replication in the New Zealand rabbit ocular model. METHODS: In a series of four experiments using a two-eye design, a total of 80 New Zealand rabbits were inoculated in both eyes with HSV-1 McKrae after epithelial scarification. Forty-eight hours after inoculation, the rabbits were randomly assigned to a treatment group. Five treatment groups (16 rabbits/group) were evaluated: I, 1% cidofovir, twice daily for 7 days; II, 0.5% cidofovir, twice daily for 7 days; III, 3% acyclovir ointment, five times daily for 7 days; IV, 1% trifluridine, nine times daily for 3 days, then 4 times daily for 4 days; and V, control vehicle twice daily for 7 days. HSV-1 dendritic keratitis was graded in a masked fashion by slit-lamp examination on days 2, 3, 5, 7, 9, 11, and 14. Ocular viral cultures were obtained after slit-lamp examination on days 1, 3, 5, 7, 9, 11, and 14. RESULTS: Compared with the control group, all four treatment groups demonstrated significantly lower viral titers, fewer HSV-1-positive eyes/total during the treatment period, lower keratitis scores, fewer eyes with keratitis/total, and a shorter time to resolution of keratitis. Within the treatment groups, the 1% and 0.5% cidofovir treatments were significantly more effective than acyclovir and trifluridine as measured by the previous viral and keratitis parameters. CONCLUSIONS: Topical 1% and 0.5% cidofovir both appeared to be significantly more efficacious than topical trifluridine and acyclovir, during a 7-day course, in the treatment of experimental HSV-1 ocular disease in the New Zealand rabbit keratitis model.

Acyclovir↗

PubMed1998

The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication.

OBJECTIVE: To evaluate the antiviral activity of topical diclofenac sodium (Voltaren Ophthalmic) and ketorolac tromethamine (Acular) (2 nonsteroidal anti-inflammatory drugs [NSAIDs]) on adenoviral replication in vitro and in the adenovirus (Ad) 5 McEwen-New Zealand rabbit ocular model. METHODS: The 50% inhibitory concentration of ketorolac and diclofenac and their respective preservative components were determined for common ocular adenoviral serotypes (Ad8, Ad19, Ad1, and Ad5). In a series of experiments, Ad5 McEwen-inoculated New Zealand rabbit eyes were treated topically 4 times daily for 18 days with either ketorolac, diclofenac, prednisolone acetate (Pred Forte), or control vehicle (Comfort Tears). MAIN OUTCOME MEASURES: Outcome measures included serial ocular tear film titers and the formation of subepithelial immune corneal infiltrates. RESULTS: In vitro, neither ketorolac nor diclofenac demonstrated significant inhibitory activity against Ad1, Ad5, Ad8, or Ad19. In the rabbit model, there were no statistically significant differences among ketorolac, diclofenac, and the control vehicle with respect to viral replication or the formation of subepithelial immune infiltrates. In contrast, 1% prednisolone prolonged viral shedding and inhibited immune infiltrates (P < .001 for both). CONCLUSIONS: Our experimental study suggests that treatment of epidemic keratoconjunctivitis with topical NSAIDs may be a safer alternative than topical steroids. Only controlled clinical trials can determine whether topical NSAIDs can provide symptomatic relief and not interfere with normal viral clearance.

Adenoviridae↗

PubMed1998

The survival of adenovirus in multidose bottles of topical fluorescein.

PURPOSE: To determine if common ocular adenovirus serotypes survive in vitro in multidose bottles of topical fluorescein (Fluress; Pilkington Barnes Hind, Inc, Sunnyvale, California). METHODS: Clinical isolates of adenovirus types 8 and 19 were inoculated separately into 10 bottles each of Fluress and maintained at room temperature (25 C). All bottles were titered for adenovirus on A549 cell monolayers at 0, 7, 14, 21, 28, and 49 days. RESULTS: Adenovirus was recovered from Fluress for up to 21 days for adenovirus type 19 and 28 days for adenovirus type 8. CONCLUSION: A multidose bottle of Fluress contaminated with adenovirus can be a potential source of adenoviral transmission in an ophthalmic office setting.

Adenovirus Infections, Human↗

PubMed1998

Efficient reactivation of latent herpes simplex virus type 1 infection by excimer laser keratectomy in the experimental rabbit ocular model.

PURPOSE: To investigate the role of excimer laser keratectomy as a trigger for the reactivation of latent HSV type 1 (HSV-1) in the New Zealand rabbit ocular model. There are conflicting reports in the current literature about reactivation of HSV-1 after excimer laser photoablation. METHODS: New Zealand rabbits were inoculated topically with HSV-1 McKrae or W strain in each eye, and culture-positive dendritic keratitis was documented on day 7. After the establishment of latency (21+ days), animals were divided into three groups: group I animals underwent excimer laser photoablation in each eye; group II animals received intrastromal injections of sterile water to act as positive controls (a standard method); and group III animals received no treatment and represented spontaneous shedders. All eyes were swabbed daily from days 1 through 10 and plated on A549 cells. Recovery of HSV-1 on days 1 through 10 postinduction was analyzed to compare the efficiency of the different methods of viral reactivation. RESULTS: Reactivation of latent HSV-1 after excimer treatment was observed in nine (45%) of 20 eyes and was equivalent to the rate of reactivation seen in the positive control animals (eight [44.4%] of 18 eyes) (P=.99). Both of these rates were significantly greater than those of the untreated animals (one [5.6%] of 18 eyes) (P=.018). CONCLUSION: Excimer laser keratectomy appears to be an efficient trigger for the reactivation of latent HSV-1 in the New Zealand rabbit ocular model.

Animals↗

PubMed1998

Multiple adenoviral serotypes demonstrate host range extension in the New Zealand rabbit ocular model.

PURPOSE: Although several human adenoviral serotypes demonstrated the genetic capability of replicating in New Zealand rabbit corneas in organ culture, only a single adenovirus (Ad) serotype, Ad5, has been reported to replicate in vivo in New Zealand rabbit eyes. The purpose of this study was to determine whether additional adenoviral serotypes could extend their host range to the New Zealand rabbit ocular model. METHODS: Six rabbits per viral isolate were inoculated in each eye after corneal scarification with 1.5 x 10(6) plaque-forming units per eye with one of the following reference or clinical adenovirus isolates: Ad1 ATCC, Ad1 Kmetz, Ad2 ATCC, Ad2 Wolf, Ad5 ATCC, Ad5 McEwen, Ad6 ATCC, Ad 19 ATCC, and Ad8 Cray (five rabbits). Eyes were cultured on days 0, 1, 3, 4, 5, 7, 9, 11, 14, 16, 18, and 21 after inoculation, and their tear film viral titers were determined on A549 cells. RESULTS: Ad19 ATCC and Ad8 Cray demonstrated no apparent viral replication. The mean duration of shedding was 1.5 and 0.3 days, respectively, and the total percentage of Ad-positive eyes was 13% and 3%, respectively. In contrast to Ad19 ATCC and Ad8 Cray, all other isolates demonstrated productive infection. The mean duration of shedding was 8 to 16 days (P < 0.0001), and the total percentage of Ad-positive eyes was 33% to 79% (P < 0.0002). The durations of shedding for Ad1 ATCC, Ad1 Kmetz, Ad2 ATCC, Ad2 Wolf, and Ad6 ATCC did not differ statistically from Ad5 McEwen, whereas Ad5 ATCC demonstrated a duration of shedding longer than all isolates (P < 0.0001). CONCLUSIONS: This was the first demonstration of host range extension by additional clinical and reference isolates of adenovirus types 1, 2, 5, and 6 in the New Zealand rabbit ocular model. These results suggested that host specificity was less stringent than previously thought.

Adenoviruses, Human↗

PubMed1998

Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.

PURPOSE: We compared the in vitro susceptibility of gram-positive bacteria to ciprofloxacin and ofloxacin using human corneal susceptibility levels. METHODS: The concentrations of ciprofloxacin and ofloxacin that can be attained in 99% of human corneas (Cornea99) after topical administration were calculated statistically from reported data. The minimal inhibitory concentrations (MICs) were determined for 95 corneal isolates of gram-positive bacteria (51 Staphylococcus aureus, 16 Streptococcus pneumoniae, 16 Streptococcus viridans group, and 12 coagulase-negative staphylococci). Susceptibility was interpreted by comparing the MICs with the respective Cornea99 for each antibiotic. Time-kill studies of representative gram-positive bacteria were tested using the Cornea99 and the maximal corneal concentrations reported for ciprofloxacin and ofloxacin. RESULTS: The Cornea99 of ciprofloxacin and ofloxacin were calculated to be 3.57 microg/ml (n = 22) and 2.22 microg/ml (n = 20), respectively. The reported mean corneal concentrations of ciprofloxacin (6.90 +/- 6.20 microg/ml) and ofloxacin (5.71 +/- 6.15 microg/ml) were comparable (p = 0.54). All gram-positive bacteria were equally susceptible to ciprofloxacin and ofloxacin (p = 0.54) based on the Cornea99. The time-kill studies determined that 8-24 h were required for both ciprofloxacin and ofloxacin to reach bactericidal levels. CONCLUSION: Ciprofloxacin and ofloxacin demonstrated comparable penetration into the cornea and provided equivalent in vitro efficacy against representative gram-positive bacteria. Time-kill studies indicated that 8-24 h of continual corneal concentrations of ciprofloxacin and ofloxacin were necessary in this study to reduce susceptible gram-positive bacteria by 99.9%.

Anti-Infective Agents↗

PubMed1997

Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.

PURPOSE: To determine how the addition of topical corticosteroids would affect the anti-adenoviral inhibitory effect of topical cidofovir (S-HPMPC) in the Ad5 New Zealand (Ad5/NZ) rabbit ocular model. METHODS: In a series of experiments (two-eye design), Ad5-inoculated/NZ rabbits (10(6) pfu/eye) were treated with 1 of 3 treatment regimens. Group 1 was administered 1% cidofovir (CDV) twice a day for 3 days plus comfort tears four times a day for 14 days. Group 2 was administered 1% CDV twice a day for 3 days plus 1% Pred Forte four times a day for 14 days. Group 3 was administered vehicle twice a day for 3 days plus comfort tears four times a day for 14 days and served as the control. All eyes were evaluated for 21 days for serial eye titers, Ad5 positive eyes, and duration of Ad5 shedding. RESULTS: Compared to control eyes in the Ad5/NZ rabbit ocular model, CDV alone demonstrated a significant antiviral inhibitory effect: reduced mean Ad5 eye titer during the early phase of infection (days 3 to 7), fewer Ad5-positive eyes during the early and late (days 9 to 21) phases of infection, and shortened duration of shedding. However, concomitant treatment with both Pred Forte and CDV significantly reversed the antiviral inhibitory activity of CDV: increased mean Ad5 eye titer, increased Ad5-positive eyes (early and late phases) and prolonged duration of shedding. CONCLUSIONS: These experimental data further support the clinical development of cidofovoir as a topical antiviral agent, but they do not support a treatment regimen that includes a combination of topical corticosteroids and topical cidofovir as a desirable strategy for the treatment of symptomatic adenoviral ocular infection.

Adenovirus Infections, Human↗

PubMed1996

The effects of corticosteroids of adenoviral replication.

OBJECTIVE: To evaluate the effects of Pred Forte (prednisolone acetate; Allergan Pharmaceutical, Irvine, Calif) on the replication of different adenoviral serotypes in vitro and in the adenovirus type 5/New Zealand rabbit ocular model. METHODS: The 50% inhibitory doses of Pred Forte and its components were determined for common ocular serotypes. The effects of continuous topical treatment with Pred Forte for 18 days were evaluated (eg, conjunctivitis, subepithelial immune infiltrates, and serial ocular viral titers) in the adenovirus 5/New Zealand rabbit ocular model. RESULTS: Pred Forte and prednisolone acetate inhibited adenoviruses 1, 5, 8, and 19 in vitro. In vivo, 1% Pred Forte significantly reduced conjunctivitis (P = .04) and subepithelial infiltrates (P = .02), but enhanced viral replication (P = .01) on days 9 to 21 and increased the duration of viral shedding (P < .001). CONCLUSIONS: Despite demonstrated anti-inflammatory and anti-immune effects, prolonged treatment of acute adenoviral infections with topical Pred Forte is not recommended because of the enhanced risks of viral transmission and community epidemics.

Adenoviridae Infections↗

PubMed1996

Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis.

PURPOSE: We evaluated patients' hands as a possible vector for the spread of epidemic kerato-conjunctivitis. METHODS: The hands and conjunctivitis of 26 patients with epidemic keratoconjunctivitis and the hands of 26 uninfected control patients were cultured for infectious adenovirus. RESULTS: In 12 (46%) of 26 patients with epidemic keratoconjunctivitis, cultures from the hands were positive for adenovirus, whereas cultures from the hands of all uninfected control patients were negative. CONCLUSIONS: Simultaneous coinfection of patients' hands and eyes with adenovirus may contribute to office epidemics. Ophthalmologists and coworkers should not shake the hands of patients suspected of having epidemic keratoconjunctivitis unless properly gloved.

Adenovirus Infections, Human↗

PubMed1996

Fluoroquinolones in the treatment of bacterial keratitis.

PURPOSE: We evaluated the potential role of three topical fluoroquinolones in the treatment of bacterial keratitis by means of a laboratory database. METHODS: Antibiotic susceptibilities were determined for 153 isolates from patients with bacterial keratitis. Results were analyzed for each fluoroquinolone individually and in combination with cefazolin. RESULTS: Predicted susceptibility to each cefazolin-fluoroquinolone combination (98.7%) was superior to that for single-agent therapy with ofloxacin (88.2%), ciprofloxacin (82.3%), or norfloxacin (80.4%) (P = .0002). A cefazolin-fluoroquinolone combination (98.7%) was comparable to a cefazolin-gentamicin combination (97.4%). CONCLUSIONS: Combination therapy with cefazolin and a fluoroquinolone offers a reasonable alternative for the treatment of bacterial keratitis. Single-agent therapy with fluoroquinolones for vision-threatening bacterial keratitis is not advised.

Anti-Bacterial Agents↗

PubMed1996

A 5-year evaluation of the adenoclone test for the rapid diagnosis of adenovirus from conjunctival swabs.

The rapid diagnosis of adenoviral ocular infections affords the opportunity to limit the transmission of virus within the community and avoid expensive, unnecessary, and ineffective therapy. This study evaluated the results of a 5-year experience with the Adenoclone test (Cambridge Biotech, Worcester, MA), an enzyme immunoassay, applied directly to conjunctival swabs obtained from infected eyes. The sensitivity of this test was determined on 372 consecutive adenovirus culture-positive ocular specimens. A subset of 106 specimens was evaluated, including a retrospective chart review to determine the relationship between the Adenoclone result and the time to viral cytopathic effect (CPE) in A549 cell culture, ocular titers (90% tissue culture infectious dose; TCID90), serotype, and associated clinical parameters. Overall, the sensitivity for Adenoclone was 38% (142 of 372), which improved to 65% (129 of 199) for samples positive in culture during the first week. A positive Adenoclone test result was associated with a shorter time to CPE in cell culture (p = 0.0001). The mean ocular titers (log TCID90) associated with a positive test result were found to be at a significantly higher dilution than a negative result (-1.70 +/- 0.93 vs. -0.88 +/- 1.00, p < 0.0001). A positive Adenoclone outcome was independent of the serotype but directly associated with a recent visit to an ophthalmologist's office, follicular conjunctivitis, and conjunctival chemosis. For the rapid diagnosis of adenoviral ocular infections, the Adenoclone test remains useful, but a more sensitive test based on nonradioactive amplification is eagerly anticipated.

Adenoviridae↗